Imunon stock analysis
Imunon (CBO0) Stock Price & Analysis
CBO0 Stock Chart & Stats
- Day’s Range
- EUR 0.55 - EUR 0.71
- 52-Week Range
- EUR 0.52 - EUR 3.54
- Previous Close
- EUR 0.52
- Volume
- N/A
- Average Volume (3M)
- 22
- Market Cap
- EUR 3.70M
- Enterprise Value
- EUR 10.57M
- Total Cash (Recent Filing)
- EUR 4.04M
- Total Debt (Recent Filing)
- EUR 6.94M
- Price to Earnings (P/E)
- ―
- Beta
- 0.15
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Encouraging IMNN-001 Clinical Signals
Early randomized clinical findings support the biological activity of IMNN-001, while the company also reported favorable safety across studies. Although preliminary and not confirmatory, these signals could strengthen the asset’s development rationale and support continued investment in the pivotal program.
NCI Collaboration Expands Development
The NCI collaboration broadens IMNN-001’s potential clinical application while transferring regulatory and operational responsibility for new studies to a major research partner. This can generate additional evidence and expand the pipeline without diverting as many company resources from OVATION-3.
OVATION-3 Enrollment Productivity
Enrollment above plan provides evidence that the pivotal OVATION-3 trial is progressing with operational productivity at active sites. Sustained execution could improve confidence in the development pathway, support milestone delivery, and help advance IMNN-001 toward a potentially registrational outcome.
Bears Say
Going-concern And Funding Risk
The going-concern disclosure indicates that available liquidity is not sufficient to support the business comfortably through its development plans. This creates persistent financing dependence, increases uncertainty around program continuity, and may constrain strategic flexibility over the next several quarters.
Persistent Losses And Cash Burn
Imunon has no meaningful commercial revenue base and continues to convert operating activity into substantial losses and cash outflows. Until a product generates sales or a program reaches monetization, this economics profile limits self-funding capacity and reinforces the need for external capital.
Trial Completion Depends On Financing And Execution
The pivotal program’s value depends on both securing additional funding and maintaining enrollment performance across a larger site network. Delays or weaker execution could extend the path to interim analysis, increase development spending, and postpone any potential regulatory or commercial benefits.
Imunon News
CBO0 FAQ
What was Imunon’s price range in the past 12 months?
What is Imunon’s market cap?
When is Imunon’s upcoming earnings report date?
How were Imunon’s earnings last quarter?
Is Imunon overvalued?
Does Imunon pay dividends?
What is Imunon’s EPS estimate?
How many shares outstanding does Imunon have?
What happened to Imunon’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Imunon?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Imunon
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stacy R. Lindborg
- Employees
- 20
- Website
- www.imunon.com
- Address
- 997 Lenox Drive, Lawrenceville, NJ, 08648, US
Imunon (CBO0) Earnings & Revenues
CBO0 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive regarding IMNN-001, with management highlighting strong OVATION-3 enrollment productivity, favorable safety findings, encouraging preliminary MRD data, supportive overall survival results from OVATION-2, independent validation, and portfolio and balance-sheet actions focused on the Phase III program. However, the company continues to face substantial financing risk, disclosed substantial doubt about its ability to continue as a going concern, and requires additional capital to complete OVATION-3. The positive clinical and operational updates significantly outweighed the stated financial and execution challenges.
View all DE:CBO0 earnings summariesCBO0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |












